Search results
Results from the WOW.Com Content Network
Post-chemotherapy cognitive impairment (PCCI) (also known in the scientific community as " CRCIs or Chemotherapy-Related Cognitive Impairments " and in lay terms as chemotherapy-induced cognitive dysfunction or impairment, chemo brain, or chemo fog) describes the cognitive impairment that can result from chemotherapy treatment.
Alzheimer's disease (AD) is a neurodegenerative disease that usually starts slowly and progressively worsens, [2] and is the cause of 60–70% of cases of dementia. [2][15] The most common early symptom is difficulty in remembering recent events. [1] As the disease advances, symptoms can include problems with language, disorientation (including ...
2.4 million (2016) [9] Dementia is a syndrome associated with many neurodegenerative diseases, characterized by a general decline in cognitive abilities that affects a person's ability to perform everyday activities. This typically involves problems with memory, thinking, behavior, and motor control. [10]
Research suggests that exercising improves cognitive processes and memory, while increasing the thickness of your cerebral cortex, which is responsible for tasks like language, thinking, and ...
After 670 days, there were 1,172 new diagnoses of dementia among the study participants. When compared with people who took DPP-4 inhibitors, those who took SGLT-2 inhibitors had a 35 percent ...
Chemotherapy regimen. A chemotherapy regimen is a regimen for chemotherapy, defining the drugs to be used, their dosage, the frequency and duration of treatments, and other considerations. In modern oncology, many regimens combine several chemotherapy drugs in combination chemotherapy. The majority of drugs used in cancer chemotherapy are ...
The Dementia Training Australia funding an interactive online education package for deprescribing in dementia centered around the MATCH-D. It was a joint collaboration between the University of Western Australia, University of Tasmania, La Trobe University, Monash University, Alfred Health and FireFilms.
Hormone-modulating therapy for breast cancer is associated with a 7% lower risk of developing Alzheimer's disease and related dementias later in life, a new study indicates.